This study is an extension of the original placebo-controlled trial to determine the safety and efficacy of Copolymer I in patients with relapsing-remitting multiple sclerosis. The controlled phase 3 trial showed that treatment with copolymer 1 was effective in reducing the clinical relapses and in slowing accumulated neurological disability compared to placebo treated patients. Most patients completing the phase 3 placebo controlled study elected to enroll in this open-labeled extension study of copolymer 1 for determination of long term safety and apparent persistence of efficacy. The study will be extended for a minimum of two additional years with the evaluation of all enrolled patients with annual quantitative magnetic resonance imaging, with centralized image analysis conducted at the University of Texas-Houston, Health Science Center.
Showing the most recent 10 out of 396 publications